1. A light sensor comprising:
a substrate having a surface;
one or more photodetectors disposed proximate to the substrate and configured to detect light and to provide a signal in response thereto;
one or more color pass filters disposed proximate to the surface, the one or more color pass filters configured to filter visible light to pass light in a limited spectrum of wavelengths to the one or more photodetectors;
an IR cut interference filter disposed over the one or more photodetectors, the IR cut interference filter configured to filter infrared light to at least substantially block infrared light from reaching the one or more photodetectors;
an adhesion layer disposed between the surface and the one or more color pass filters; and
an insulation layer disposed over the surface such that the insulation layer substantially encloses the one or more color pass filters and the IR cut interference filter.
2. The light sensor as recited in claim 1, further comprising a buffer layer disposed over the surface of the substrate to facilitate formation of at least one of the IR cut interference or the color pass filter.
3. The light sensor as recited in claim 1, wherein at least one of the one or more photodetectors comprises a clear photodetector, the clear photodetector configured to receive light unfiltered by the one or more color pass filters to detect an ambient light environment.
4. The light sensor as recited in claim 1, wherein the IR cut interference filter is a patternable IR cut interference filter.
5. The light sensor as recited in claim 1, further comprising a dark mirror edge disposed about a periphery of the IR cut interference filter, the dark mirror edge configured to at least substantially eliminate impingement of light that does not pass through the IR cut interference filter.
6. A light sensor comprising:
a substrate having a surface;
one or more photodetectors disposed proximate to the substrate, the one or more photodetectors configured to detect light and provide a signal in response thereto;
an IR interference filter disposed over the surface, the IR interference filter configured to filter infrared light to at least substantially block infrared light from reaching the one or more photodetectors;
one or more color pass filters disposed proximate to the IR interference filter and configured to filter visible light to pass light in a limited spectrum of wavelengths to the one or more photodetectors;
a buffer layer disposed over the surface of the substrate to facilitate formation of at least one of the IR interference or the color pass filter; and
an adhesion layer disposed over the surface for holding the one or more color pass filters in position.
7. The light sensor as recited in claim 6, further comprising a dark mirror edge disposed about a periphery of the IR interference filter, the dark mirror edge configured to at least substantially eliminate impingement of light that does not pass through the IR interference filter.
8. The light sensor as recited in claim 6, wherein the one or more color pass filters are disposed on the adhesion layer, the buffer layer is formed over the surface such that the buffer layer substantially encloses the one or more color pass filters, and the IR interference filter is formed at least partially over the buffer layer.
9. The light sensor as recited in claim 6, wherein the one or more photodetectors comprises a clear photodetector, the clear photodetector configured to receive light unfiltered by a color pass filter to detect an ambient light environment.
10. The light sensor as recited in claim 6, wherein the one or more photodetectors comprise at least one of photodiodes or phototransistors.
11. A process comprising:
providing one or more photodetectors in or on a substrate, the one or more photodetectors configured to detect light and to provide a signal in response thereto;
providing an adhesion layer over the surface, the adhesion layer configured to hold the one or more color pass filters in position;
providing the one or more color sass filters on the adhesion layer the one or more color pass filters configured to filter visible light to pass light in a limited spectrum of wavelengths to the one or more photodetectors;
providing the buffer layer over the surface of the substrate such that the buffer layer substantially encloses the one or more color pass filters to protect and insulate the one or more color pass filters;
providing an IR cut interference filter over the surface of the buffer layer, the IR cut interference filter configured to configured to at least substantially block infrared light from reaching the surface, wherein the IR cut interference filter is at least substantially coextensive with the one or more color pass filters.
12. The process as recited in claim 11, further comprising:
providing the IR cut interference filter over the surface of the substrate;
providing the buffer layer over the IR cut interference filter;
planarizing at least a portion of the buffer layer;
providing the adhesion layer on a surface of the IR cut interference filter; and
providing the one or more color pass filters on the adhesion layer.
13. The process as recited in claim 11, further comprising providing a dark mirror edge about the IR cut interference filter and the buffer layer, the dark mirror edge configured to at least substantially eliminate impingement of light that does not pass through the IR cut interference filter onto the one or more photodetectors.
14. The process as recited in claim 11, wherein the buffer layer comprises a Benzocyclobutene (BCB) polymer.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for inhibiting undesired cell migration, cell invasion, cell proliferation or angiogenesis in vivo, or for inducing apoptosis in vivo, comprising administering to a subject in need thereof an effective amount of:
(a) a polypeptide that is
(i) a variant of native HK-D3 (SEQ ID NO: 1) designated HK-D3v, which has the amino acid sequence SEQ ID NO: 3, or
(ii) a variant of native HK-D3 (SEQ ID NO: 1) that has an N-terminal addition and has the sequence SEQ ID NO: 2,
wherein the polypeptide has at least 20% of the activity of native HK-D3 (SEQ ID NO: 1) in inhibiting angiogenesis, endothelial cell proliferation or endothelial tube formation in an in vitro or in vivo bioassay, or
(b) an anti-angiogenic pharmaceutical composition that comprises the polypeptide of
(a) and a pharmaceutically acceptable carrier,
thereby inhibiting said undesired cell migration, cell invasion, cell proliferation or angiogenesis, or inducing apoptosis.
2. The method of claim 1, wherein the polypeptide or variant is therapeutically labeled by direct or indirect binding of a therapeutically active moiety.
3. The method of claim 2 wherein the therapeutically active moiety is a radionuclide.
4. The method of claim 3, wherein the radionuclide is selected from the group consisting of 47Sc, 67Cu, 90Y, 109Pd, 125I, 131I, 186Re, 188Re, 199Au, 211At, 212Pb and 217Bi.
5. A method for treating a subject having a disease or condition associated with undesired cell migration, cell invasion, cell proliferation, or angiogenesis, which method comprises administering to the subject an effective amount of an anti-angiogenic pharmaceutical composition that comprises:
(a) a polypeptide that is
(i) a variant of native HK-D3 (SEQ ID NO: 1) designated HK-D3v, which has the amino acid sequence SEQ ID NO: 3, or
(ii) a variant of native HK-D3 (SEQ ID NO: 1) that has an N-terminal addition and has the sequence SEQ ID NO: 2,
wherein the polypeptide has at least 20% of the activity of native HK-D3 (SEQ ID NO: 1) in inhibiting angiogenesis, endothelial cell proliferation or endothelial tube formation in an in vitro or in vivo bioassay, and
(b) a pharmaceutically acceptable carrier,
thereby treating said subject.
6. The method of claim 5 wherein administering is by injection or infusion.
7. The method of claim 5 wherein the administering is regional.
8. The method of claim 5 wherein the administering is local.
9. The method of claim 5 wherein the administering is topical.
10. The method of claim 5, wherein the polypeptide or variant is therapeutically labeled by direct or indirect binding of a therapeutically active moiety.
11. The method of claim 10 wherein the therapeutically active moiety is a radionuclide.
12. The method of claim 11, wherein the radionuclide is selected from the group consisting of 47Sc, 67Cu, 90Y, 109Pd, 125I, 131I, 186Re, 188Re, 199Au, 211At, 212Pb, and 217Bi.
13. The method of claim 10 wherein the therapeutically active moiety is a polypeptide toxin.
14. The method of claim 13 wherein the polypeptide toxin is of plant or bacterial origin.
15. The method of claim 14 wherein the polypeptide toxin is ricin, abrin, diphtheria toxin or Pseudomonas exotoxin A.
16. The method of claim 10 wherein the therapeutically active moiety is a small organic cytotoxic drug.
17. The method of claim 16 wherein the cytotoxic drug is daunorubicin, doxorubicin, methotrexate, or mitomycin C.